601 related articles for article (PubMed ID: 11095447)
1. Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism.
Kumeda Y; Inaba M; Tahara H; Kurioka Y; Ishikawa T; Morii H; Nishizawa Y
J Clin Endocrinol Metab; 2000 Nov; 85(11):4157-61. PubMed ID: 11095447
[TBL] [Abstract][Full Text] [Related]
2. Changes in parameters of bone and mineral metabolism during therapy for hyperthyroidism.
Pantazi H; Papapetrou PD
J Clin Endocrinol Metab; 2000 Mar; 85(3):1099-106. PubMed ID: 10720046
[TBL] [Abstract][Full Text] [Related]
3. Studies of thyroid function and immune parameters in patients with hyperthyroid Graves' disease in remission.
Murakami M; Koizumi Y; Aizawa T; Yamada T; Takahashi Y; Watanabe T; Kamoi K
J Clin Endocrinol Metab; 1988 Jan; 66(1):103-8. PubMed ID: 3121661
[TBL] [Abstract][Full Text] [Related]
4. Bone remodelling markers and serum cytokines in patients with hyperthyroidism.
Akalin A; Colak O; Alatas O; Efe B
Clin Endocrinol (Oxf); 2002 Jul; 57(1):125-9. PubMed ID: 12100080
[TBL] [Abstract][Full Text] [Related]
5. Decreased serum level of IL-7 in patients with active Graves' disease.
Motylewska E; Nieć M; Siejka A; Komorowski J; Ławnicka H; Świętosławski J; Stępień H
Cytokine; 2015 Oct; 75(2):373-9. PubMed ID: 26113403
[TBL] [Abstract][Full Text] [Related]
6. Thyrotropin versus thyroid hormone in regulating bone density and turnover in premenopausal women.
Baqi L; Payer J; Killinger Z; Hruzikova P; Cierny D; Susienkova K; Langer P
Endocr Regul; 2010 Apr; 44(2):57-63. PubMed ID: 20429634
[TBL] [Abstract][Full Text] [Related]
7. Effect of 1 alpha-hydroxyvitamin D3 on serum levels of thyroid hormones in hyperthyroid patients with untreated Graves' disease.
Kawakami-Tani T; Fukawa E; Tanaka H; Abe Y; Makino I
Metabolism; 1997 Oct; 46(10):1184-8. PubMed ID: 9322804
[TBL] [Abstract][Full Text] [Related]
8. High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment.
Amato G; Mazziotti G; Sorvillo F; Piscopo M; Lalli E; Biondi B; Iorio S; Molinari A; Giustina A; Carella C
Bone; 2004 Sep; 35(3):785-91. PubMed ID: 15336617
[TBL] [Abstract][Full Text] [Related]
9. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
Quadbeck B; Hoermann R; Roggenbuck U; Hahn S; Mann K; Janssen OE;
Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
[TBL] [Abstract][Full Text] [Related]
10. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
Chung YJ; Lee BW; Kim JY; Jung JH; Min YK; Lee MS; Lee MK; Kim KW; Chung JH
Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
[TBL] [Abstract][Full Text] [Related]
11. Serum cytokines in thyrotoxicosis.
Siddiqi A; Monson JP; Wood DF; Besser GM; Burrin JM
J Clin Endocrinol Metab; 1999 Feb; 84(2):435-9. PubMed ID: 10022397
[TBL] [Abstract][Full Text] [Related]
12. Triiodothyronine-predominant Graves' disease in childhood: detection and therapeutic implications.
Harvengt J; Boizeau P; Chevenne D; Zenaty D; Paulsen A; Simon D; Guilmin Crepon S; Alberti C; Carel JC; Léger J
Eur J Endocrinol; 2015 Jun; 172(6):715-23. PubMed ID: 25766047
[TBL] [Abstract][Full Text] [Related]
13. Markers of bone turnover in hyperthyroidism and the effects of treatment.
Garnero P; Vassy V; Bertholin A; Riou JP; Delmas PD
J Clin Endocrinol Metab; 1994 Apr; 78(4):955-9. PubMed ID: 8157727
[TBL] [Abstract][Full Text] [Related]
14. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' orbitopathy.
Lytton SD; Ponto KA; Kanitz M; Matheis N; Kohn LD; Kahaly GJ
J Clin Endocrinol Metab; 2010 May; 95(5):2123-31. PubMed ID: 20237164
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of bone turnover markers and thyroid indicators for bone metabolism in GD patients after treatment.
Su M; Chai J; Zheng W; Jia Q; Tan J; He Y; Zhang R; Men J; Liu W; Shi T; Ren J; Dong L; Liu L; Meng Z
Front Endocrinol (Lausanne); 2024; 15():1301213. PubMed ID: 38742199
[TBL] [Abstract][Full Text] [Related]
16. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
Rittmaster RS; Zwicker H; Abbott EC; Douglas R; Givner ML; Gupta MK; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084
[TBL] [Abstract][Full Text] [Related]
17. [Changes of bone and mineral metabolism in patients with hyperthyroidism before and after treatment].
Chai R; Ye Z; Zhan Z
Zhonghua Yi Xue Za Zhi; 1998 Sep; 78(9):682-4. PubMed ID: 11038794
[TBL] [Abstract][Full Text] [Related]
18. Thyrotropin receptor autoantibodies are associated with continued thyrotropin suppression in treated euthyroid Graves' disease patients.
Brokken LJ; Wiersinga WM; Prummel MF
J Clin Endocrinol Metab; 2003 Sep; 88(9):4135-8. PubMed ID: 12970276
[TBL] [Abstract][Full Text] [Related]
19. Relationship between CTLA-4 and CD28 molecule expression on T lymphocytes and stimulating and blocking autoantibodies to the TSH-receptor in children with Graves' disease.
Bossowski A; Stasiak-Barmuta A; Urban M
Horm Res; 2005; 64(4):189-97. PubMed ID: 16220002
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma.
Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Biondi B; Iorio S; Giustina A; Amato G; Carella C
J Bone Miner Res; 2005 Mar; 20(3):480-6. PubMed ID: 15746993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
